

Serial No. 10/645,784

RECEIVED
CENTRAL FAX CENTER

JUN 03 2008

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-28. (Cancelled).

29. (Previously Presented). The process of Claim 46, wherein the gene construct is expressed in an *E. coli* cell.

30-45. (Cancelled).

46. (Amended). A process for preparing a pharmacologically active compound, which comprises:

- (a) selecting from a peptide phage display library at least one nucleic acid sequence encoding a peptide that modulates the activity of AGP-3, wherein "peptide" refers to molecules of 2 to 40 amino acids;
- (b) preparing a gene construct that encodes comprises at least one said selected peptide sequence and an Fc domain;
- (c) expressing a pharmacologically active compound from the gene construct, wherein the gene construct encodes a compound of the formula

$(X^1)_a-F^1-(X^2)_b$

and multimers thereof, wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$;

P^1 , P^2 , P^3 , and P^4 are each independently encoded by the selected peptide sequences;

L^1 , L^2 , L^3 , and L^4 are each independently linkers; and
a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1

- (c) expressing the pharmacologically active compound comprising the Fc-peptide fusion protein from said gene construct; and
- (d) isolating said expressed protein, wherein said isolated protein modulates the activity of AGP-3.

Serial No. 10/645,784

47. (Original). The process of Claim 46, wherein the compound prepared is of the formulae

$$X^1-F^1$$

or

$$F^1-X^2.$$

48. (Original). The process of Claim 46, wherein the compound prepared is of the formulae

$$F^1-(L^1)_c-P^1$$

or

$$F^1-(L^1)_c-P^1-(L^2)_d-P^2.$$

49. (Original). The process of Claim 46, wherein F^1 is an IgG Fc domain.

50. (Original). The process of Claim 46, wherein F^1 is an IgG1 Fc domain.

51. (Original). The process of Claim 46, wherein F^1 comprises the sequence of SEQ ID NO: 2.

Claims 52-62 (Canceled).

63. (Previously Presented). The process of Claim 46 wherein a is 1 and b is 0.

64. (Previously Presented). The process of Claim 46 wherein X^1 is $-(L^1)_c-P^1-(L^2)_d-P^2$.

65. (Previously Presented). The process of Claim 63 wherein X^1 is $-(L^1)_c-P^1-(L^2)_d-P^2$.

66. (Previously Presented). The process of Claim 65 wherein L^1 is (Gly)₅.

67. (Previously Presented). The process of Claim 65 wherein L^2 is (Gly)₅.

68. (Previously Presented). The process of Claim 66 wherein L^2 is (Gly)₅.

69-79. (Canceled).